368 related articles for article (PubMed ID: 15169827)
1. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
Jones DC; Lau SS; Monks TJ
J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
[TBL] [Abstract][Full Text] [Related]
2. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats.
Miller RT; Lau SS; Monks TJ
Chem Res Toxicol; 1996 Mar; 9(2):457-65. PubMed ID: 8839050
[TBL] [Abstract][Full Text] [Related]
3. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells.
Carvalho M; Hawksworth G; Milhazes N; Borges F; Monks TJ; Fernandes E; Carvalho F; Bastos ML
Arch Toxicol; 2002 Oct; 76(10):581-8. PubMed ID: 12373454
[TBL] [Abstract][Full Text] [Related]
4. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.
Bai F; Lau SS; Monks TJ
Chem Res Toxicol; 1999 Dec; 12(12):1150-7. PubMed ID: 10604863
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.
Bai F; Jones DC; Lau SS; Monks TJ
Chem Res Toxicol; 2001 Jul; 14(7):863-70. PubMed ID: 11453733
[TBL] [Abstract][Full Text] [Related]
7. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro.
Carvalho M; Remião F; Milhazes N; Borges F; Fernandes E; Monteiro Mdo C; Gonçalves MJ; Seabra V; Amado F; Carvalho F; Bastos ML
Chem Res Toxicol; 2004 May; 17(5):623-32. PubMed ID: 15144219
[TBL] [Abstract][Full Text] [Related]
8. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.
Monks TJ; Jones DC; Bai F; Lau SS
Ther Drug Monit; 2004 Apr; 26(2):132-6. PubMed ID: 15228153
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.
Capela JP; Meisel A; Abreu AR; Branco PS; Ferreira LM; Lobo AM; Remião F; Bastos ML; Carvalho F
J Pharmacol Exp Ther; 2006 Jan; 316(1):53-61. PubMed ID: 16183702
[TBL] [Abstract][Full Text] [Related]
10. Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catechol-thioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling.
Felim A; Urios A; Neudörffer A; Herrera G; Blanco M; Largeron M
Chem Res Toxicol; 2007 Apr; 20(4):685-93. PubMed ID: 17355154
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates.
Carvalho M; Milhazes N; Remião F; Borges F; Fernandes E; Amado F; Monks TJ; Carvalho F; Bastos ML
Arch Toxicol; 2004 Jan; 78(1):16-24. PubMed ID: 14586543
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain.
Erives GV; Lau SS; Monks TJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):284-91. PubMed ID: 17906065
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.
Jones DC; Duvauchelle C; Ikegami A; Olsen CM; Lau SS; de la Torre R; Monks TJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):422-31. PubMed ID: 15634943
[TBL] [Abstract][Full Text] [Related]
14. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity.
Escubedo E; Abad S; Torres I; Camarasa J; Pubill D
Neurochem Int; 2011 Jan; 58(1):92-101. PubMed ID: 21074589
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
Ferreira PS; Nogueira TB; Costa VM; Branco PS; Ferreira LM; Fernandes E; Bastos ML; Meisel A; Carvalho F; Capela JP
Toxicol Lett; 2013 Feb; 216(2-3):159-70. PubMed ID: 23194825
[TBL] [Abstract][Full Text] [Related]
16. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
Bankson MG; Cunningham KA
J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain.
Darvesh AS; Yamamoto BK; Gudelsky GA
J Pharmacol Exp Ther; 2005 Feb; 312(2):694-701. PubMed ID: 15456837
[TBL] [Abstract][Full Text] [Related]
18. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.
Schuldiner S; Steiner-Mordoch S; Yelin R; Wall SC; Rudnick G
Mol Pharmacol; 1993 Dec; 44(6):1227-31. PubMed ID: 7903417
[TBL] [Abstract][Full Text] [Related]
19. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations.
Miller RT; Lau SS; Monks TJ
Eur J Pharmacol; 1997 Apr; 323(2-3):173-80. PubMed ID: 9128836
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.
Bowyer JF; Young JF; Slikker W; Itzak Y; Mayorga AJ; Newport GD; Ali SF; Frederick DL; Paule MG
Neurotoxicology; 2003 Jun; 24(3):379-90. PubMed ID: 12782103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
